Compositions and Methods for TIGR-Tas Mediated Targeting

Patent Status

Patent Pending

Brief Description

RNA-guided DNA targeting systems have fundamentally changed the landscape of genomic research and therapeutic development, yet the large size of traditional CRISPR tools creates a "delivery bottleneck" for therapeutic vectors. While the TIGR-Tas protein family offers a compact alternative for streamlined delivery, naturally occurring TasR proteins often lack the cleavage efficiency required for complex biological environments. 

UC Berkeley researchers have overcome this by engineering high-performance variants of ParTasR. This system is approximately one-quarter the size of Cas9. The engineered proteins demonstrate significantly higher on-target cleavage activity than wild-type sequences, offering a potent and hyper-compact alternative for the next generation of in vivo genome editing.

Suggested uses

• Gene editing
• Compact Delivery Systems
• Targeted DNA Binding
• Molecular Diagnostics

Advantages

• Maximized On-Target Potency
• Compact Delivery Profile
• Optimized Targeting Precision
• Versatile Modular Platform